159 related articles for article (PubMed ID: 38097887)
1. A protective role of nintedanib in peritoneal fibrosis through H19-EZH2-KLF2 axis via impeding mesothelial-to-mesenchymal transition.
Zhong W; Fu J; Liao J; Ouyang S; Yin W; Liang Y; Liu K
Int Urol Nephrol; 2024 Jun; 56(6):1987-1999. PubMed ID: 38097887
[TBL] [Abstract][Full Text] [Related]
2. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen exerts anti-peritoneal fibrosis effects by inhibiting H19-activated VEGFA transcription.
Zhao T; Sun Z; Lai X; Lu H; Liu L; Li S; Yuan JH; Guo Z
J Transl Med; 2023 Sep; 21(1):614. PubMed ID: 37697303
[TBL] [Abstract][Full Text] [Related]
4. Asiaticoside inhibits TGF-β1-induced mesothelial-mesenchymal transition and oxidative stress via the Nrf2/HO-1 signaling pathway in the human peritoneal mesothelial cell line HMrSV5.
Zhao J; Shi J; Shan Y; Yu M; Zhu X; Zhu Y; Liu L; Sheng M
Cell Mol Biol Lett; 2020; 25():33. PubMed ID: 32514269
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of EZH2 mitigates peritoneal fibrosis and lipid precipitation in peritoneal mesothelial cells mediated by klotho.
Wang Q; Sun J; Wang R; Sun J
Ren Fail; 2023 Dec; 45(1):2149411. PubMed ID: 36724065
[TBL] [Abstract][Full Text] [Related]
6. Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-β1/Smad3 signaling pathway in vitro.
Yang Y; Liu K; Liang Y; Chen Y; Chen Y; Gong Y
Int J Clin Exp Pathol; 2015; 8(3):2746-54. PubMed ID: 26045780
[TBL] [Abstract][Full Text] [Related]
7. BMSC-derived Exosomes Ameliorate Peritoneal Dialysis-associated Peritoneal Fibrosis via the Mir-27a-3p/TP53 Pathway.
Zhao JL; Zhao L; Zhan QN; Liu M; Zhang T; Chu WW
Curr Med Sci; 2024 Apr; 44(2):333-345. PubMed ID: 38622424
[TBL] [Abstract][Full Text] [Related]
8. Effects of TGF-β1 Receptor Inhibitor GW788388 on the Epithelial to Mesenchymal Transition of Peritoneal Mesothelial Cells.
Lho Y; Do JY; Heo JY; Kim AY; Kim SW; Kang SH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947038
[TBL] [Abstract][Full Text] [Related]
9. Curcumin suppresses epithelial-to-mesenchymal transition of peritoneal mesothelial cells (HMrSV5) through regulation of transforming growth factor-activated kinase 1 (TAK1).
Zhao JL; Guo MZ; Zhu JJ; Zhang T; Min DY
Cell Mol Biol Lett; 2019; 24():32. PubMed ID: 31143210
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of EZH2 suppresses peritoneal angiogenesis by targeting a VEGFR2/ERK1/2/HIF-1α-dependent signaling pathway.
Shi Y; Li J; Chen H; Hu Y; Tang L; Wang Y; Zang X; Ma X; Huang G; Zhou X; Tao M; Lv Z; Chen S; Qiu A; Zhuang S; Liu N
J Pathol; 2022 Oct; 258(2):164-178. PubMed ID: 35792675
[TBL] [Abstract][Full Text] [Related]
11. Functional molecules in mesothelial-to-mesenchymal transition revealed by transcriptome analyses.
Namvar S; Woolf AS; Zeef LA; Wilm T; Wilm B; Herrick SE
J Pathol; 2018 Aug; 245(4):491-501. PubMed ID: 29774544
[TBL] [Abstract][Full Text] [Related]
12. Nitro-oleic acid inhibits the high glucose-induced epithelial-mesenchymal transition in peritoneal mesothelial cells and attenuates peritoneal fibrosis.
Su W; Wang H; Feng Z; Sun J
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F457-F467. PubMed ID: 31760768
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelial-to-mesenchymal transition, inflammation and angiogenesis.
Liu F; Yu C; Qin H; Zhang S; Fang L; Wang Y; Wang J; Cui B; Hu S; Liu N; Zhuang S
J Cell Mol Med; 2021 May; 25(13):6103-14. PubMed ID: 33949772
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA SNHG1 promotes bladder cancer progression by upregulating EZH2 and repressing KLF2 transcription.
Min J; Ma J; Wang Q; Yu D
Clinics (Sao Paulo); 2022; 77():100081. PubMed ID: 36087568
[TBL] [Abstract][Full Text] [Related]
15. Activation of the RAS contributes to peritoneal fibrosis via dysregulation of low-density lipoprotein receptor.
Liu J; Feng Y; Li N; Shao QY; Zhang QY; Sun C; Xu PF; Jiang CM
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F273-F284. PubMed ID: 33427062
[TBL] [Abstract][Full Text] [Related]
16. Involvement of STAT3 Signaling in High Glucose-Induced Epithelial Mesenchymal Transition in Human Peritoneal Mesothelial Cell Line HMrSV5.
Zhang P; Dai H; Peng L
Kidney Blood Press Res; 2019; 44(2):179-187. PubMed ID: 30943519
[TBL] [Abstract][Full Text] [Related]
17. HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis.
Ju KD; Kim HJ; Tsogbadrakh B; Lee J; Ryu H; Cho EJ; Hwang YH; Kim K; Yang J; Ahn C; Oh KH
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F342-50. PubMed ID: 26661649
[TBL] [Abstract][Full Text] [Related]
18. Silencing of O-linked N-acetylglucosamine transferase ameliorates hypercalcemia-induced neurotoxicity in renal failure by regulating EZH2/KLF2/CXCL1 axis.
Cao Y; Chen X; Sun H
Cell Death Dis; 2021 Aug; 12(9):819. PubMed ID: 34462420
[TBL] [Abstract][Full Text] [Related]
19. TMT quantitative proteomics and network pharmacology reveal the mechanism by which asiaticoside regulates the JAK2/STAT3 signaling pathway to inhibit peritoneal fibrosis.
Sun J; Tang L; Shan Y; Yu M; Sheng L; Huang L; Cao H; Dai H; Wang F; Zhao J; Sheng M
J Ethnopharmacol; 2023 Jun; 309():116343. PubMed ID: 36906159
[TBL] [Abstract][Full Text] [Related]
20. Parthenolide alleviates peritoneal fibrosis by inhibiting inflammation via the NF-κB/ TGF-β/Smad signaling axis.
Zhang Y; Feng W; Peng X; Zhu L; Wang Z; Shen H; Chen C; Xiao L; Li S; Zhao Y; Lin M; Huang Y; Long H; Liang J
Lab Invest; 2022 Dec; 102(12):1346-1354. PubMed ID: 36307537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
